These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1374 related items for PubMed ID: 18533124

  • 1. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population.
    Morin-Papunen L, Martikainen H, McCarthy MI, Franks S, Sovio U, Hartikainen AL, Ruokonen A, Leinonen M, Laitinen J, Järvelin MR, Pouta A.
    Am J Obstet Gynecol; 2008 Nov; 199(5):529.e1-529.e10. PubMed ID: 18533124
    [Abstract] [Full Text] [Related]

  • 2. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1.
    Pakarinen P, Lähteenmäki P, Rutanen EM.
    Acta Obstet Gynecol Scand; 1999 May; 78(5):423-8. PubMed ID: 10326889
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effects of progestin-only long-acting contraception on metabolic markers in obese women.
    Bender NM, Segall-Gutierrez P, Najera SO, Stanczyk FZ, Montoro M, Mishell DR.
    Contraception; 2013 Sep; 88(3):418-25. PubMed ID: 23410714
    [Abstract] [Full Text] [Related]

  • 6. Intrauterine devices: an effective alternative to oral hormonal contraception.
    Prescrire Int; 2009 Jun; 18(101):125-30. PubMed ID: 19637436
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The prevalence of hyperlipidemia in women and its association with use of oral contraceptives, sex hormone replacement therapy and nonlipid coronary artery disease risk factors. Canadian Heart Health Surveys Research Group.
    Connelly PW, Stachenko S, MacLean DR, Petrasovits A, Little JA.
    Can J Cardiol; 1999 Apr; 15(4):419-27. PubMed ID: 10322251
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Use of the levonorgestrel-releasing intrauterine system and breast cancer.
    Backman T, Rauramo I, Jaakkola K, Inki P, Vaahtera K, Launonen A, Koskenvuo M.
    Obstet Gynecol; 2005 Oct; 106(4):813-7. PubMed ID: 16199640
    [Abstract] [Full Text] [Related]

  • 12. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR.
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data].
    Gaspard U, Dubois M.
    Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The influence of high- and low-dose hormonal contraceptives on HDL and total cholesterol levels.
    Pretnar Darovec A, Novacan Hudnik S.
    Acta Reprod Turc; 1987 Sep; 8(3-4):37-42. PubMed ID: 12316487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.